For the @ ( @ % ) patients with BRAF ( V@E ) disease , median overall survival in the vemurafenib group was @ months ( @ % CI @-@ ) compared with @ months ( @-@ ) in the dacarbazine group ( HR @ -LSB- @ % CI @-@ -RSB- ; p = @ ) ; median progression-free survival was @ months ( @ % CI @-@ ) and @ months ( @-@ ) , respectively ( HR @ -LSB- @ % CI @-@ -RSB- ; p < @ ) .